BioSpace News Archive

Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers, today announced that Decipher Prostate RP, studied in patients from the phase III, randomized controlled trial, RTOG 96-01, demonstrated the ability to accurately identify which prostate cancer patients with recurrent disease benefit most from anti-androgen hormonal therapy

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its new drug application (NDA) for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced that Mr. Dror Ben-Asher, RedHill’s Chief Executive Officer, will present a corporate overview at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020,

Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on precision medicine cancer therapies, was featured in an interview by CEOCFO Magazine

Patients Can Now Use Site to Consult with Qualified Health Care Professionals On-Demand, Order and Potentially Receive Dermatologist-Recommended Skin Care Products

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced that its President and Chief Executive Officer, Peter L. Hoang, will present at two upcoming investor conferences.

Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the 9th Annual SVB Leerink Global Healthcare Conference

Precision Molecular, Inc. (PMI), a clinical-stage company with the mission to develop imaging biomarkers and theranostics, today announced that the Alzheimer’s Drug Discovery Foundation (ADDF) made an investment in the company to support advancement of more effective ways to image neuroinflammation, with a view to discovery of early imaging biomarkers for Alzheimer’s disease

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that full results from its Phase 2 clinical trial of zilucoplan in patients with generalized myasthenia gravis (gMG) were published online in JAMA Neurology.

Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer, today announced that Barbara S. Fox, Ph.D., the Company’s Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference